Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin

Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development

(2022) Moyang Lv et al.   CANCER LETTERS

PROTACs: Novel approach for cancer breakdown by breaking proteins

(2022) Humera Memon et al.   LIFE SCIENCES

Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1

(2021) Adam D. Cotton et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes

(2021) Da Han et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy

(2021) Peter S. Dragovich et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeted protein degraders crowd into the clinic

(2021) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer

(2021) Shipeng He et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4

(2020) Marı́a Maneiro et al.   ACS Chemical Biology

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

(2020) Sajid Khan et al.   ONCOGENE

Structure of E3 ligase E6AP with a proteasome-binding site provided by substrate receptor hRpn10

(2020) Gwen R. Buel et al.   Nature Communications

Functional characterization of a PROTAC directed against BRAF mutant V600E

(2020) Ganna Posternak et al.   Nature Chemical Biology

The PROTAC technology in drug development

(2019) Yutian Zou et al.   CELL BIOCHEMISTRY AND FUNCTION

Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)

(2019) Jiantao Hu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeted protein degradation: elements of PROTAC design

(2019) Stacey-Lynn Paiva et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Elucidation and Structural Modeling of CD71 as a Molecular Target for Cell-Specific Aptamer Binding

(2019) Xiaoqiu Wu et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity

(2019) Thomas H. Pillow et al.   ChemMedChem

Targeted protein degradation: expanding the toolbox

(2019) Matthieu Schapira et al.   NATURE REVIEWS DRUG DISCOVERY

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

(2019) Sajid Khan et al.   NATURE MEDICINE

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

(2017) Ian Churcher   JOURNAL OF MEDICINAL CHEMISTRY

A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer

(2017) Fangfei Li et al.   Nature Communications

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

(2016) Kanak Raina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin

(2016) Ye Cheng et al.   PLoS One

Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL

(2015) Ashton C. Lai et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination

(2015) Nuno A. Fonseca et al.   BIOMATERIALS

Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems

(2015) Feng Jiang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

(2014) Eric S. Fischer et al.   NATURE

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

(2013) Jonathan E. Rosenberg et al.   INVESTIGATIONAL NEW DRUGS

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

(2013) Flavia Pichiorri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Generating Aptamers by Cell-SELEX for Applications in Molecular Medicine

(2012) Mao Ye et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A New Paradigm for Aptamer Therapeutic AS1411 Action: Uptake by Macropinocytosis and Its Stimulation by a Nucleolin-Dependent Mechanism

(2010) E. M. Reyes-Reyes et al.   CANCER RESEARCH

Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells

(2009) S. Soundararajan et al.   MOLECULAR PHARMACOLOGY

Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics

(2008) Ashley R. Schneekloth et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells

(2008) S. Soundararajan et al.   CANCER RESEARCH